SCHEMBL20069737

SCHEMBL20069737

CN1CCC(C)(NC(=O)c2ccc(F)c(F)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
CNR2 P34972 1/20 0.44
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
CCNA1 P78396 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
IDO1 P14902 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
ALDH1A1 P00352 1/20 0.42
RET P07949 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
CYP2D6 P10635 2/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21504283 0.85 TAS1R3 (0.49) CNR2IDO1TAS1R3TAS1R1TAS1R2
SCHEMBL21652014 0.85 CHRM1 (0.52) MEN1KMT2ACNR2IDO1TAS1R3
SCHEMBL20147555 0.85 PLD1 (0.46) MEN1KMT2ACNR2MAOAMAOB
SCHEMBL20069759 0.84 CYP2D6 (0.57) KMT2ACYP2D6LMNAWDR5
SCHEMBL20068946 0.82 CYP2C19 (0.61) KMT2ACCNA2CDK2CCNA1ALDH1A1
SCHEMBL20069668 0.81 MAPK1 (0.44) CNR2CCNA2CDK2CCNA1RET
SCHEMBL20068950 0.80 TP53 (0.52) MEN1KMT2AWDR5
SCHEMBL20068927 0.80 CCR3 (0.45) TAS1R3TAS1R1TAS1R2RETCES2
SCHEMBL20069339 0.79 RET (0.41) MEN1KMT2ARETCYP2D6CYP2C9
SCHEMBL16565618 0.78 ATM (0.49) KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 MEN1 653/4885KMT2A 1112/4885CNR2 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.